UBT251
Vistrutide — GLP-1 / GIP / glucagon triple agonist
UBT251 (Vistrutide — GLP-1 / GIP / glucagon triple agonist) is a metabolic & fat loss research compound. A triple agonist at the GLP-1, GIP and glucagon receptors — the same three-receptor design as retatrutide. The glucagon arm is what separates the triples from the duals: glucagon raises energy expenditure directly rather than only suppressing intake, which is the mechanism the class is betting on for larger weight loss.
UBT251 quick facts
| Route | Subq |
| Frequency | 1x Weekly (trial pattern) |
| Half-life | Weekly dosing implies a long half-life; not publicly characterized |
| Forms | Injectable |
| Evidence level | Human (early clinical, United Biotechnology; rights licensed to Novo Nordisk in 2026) |
The newest thing in the GLP category and the least characterized. A major licensing deal is a signal about commercial confidence, not about a dose or a safety profile — neither of which is public. Dose-precision-critical like every compound in this class: it goes in its own syringe.
How UBT251 works
A triple agonist at the GLP-1, GIP and glucagon receptors — the same three-receptor design as retatrutide. The glucagon arm is what separates the triples from the duals: glucagon raises energy expenditure directly rather than only suppressing intake, which is the mechanism the class is betting on for larger weight loss.
Proposed benefits
Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Where to get UBT251
Buy UBT251 at Disguised Alpha →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for UBT251
Graded by what exists behind each claim.
✅ Clinically validated
- Early clinical only. A GLP-1 / GIP / glucagon triple agonist from United Biotechnology, with rights licensed to Novo Nordisk in 2026. No phase 3 data, no published dose-response.
- A licensing deal is a commercial signal, not a clinical one. It says a large company liked the early data enough to pay for it. It says nothing about the dose, the tolerability profile, or how it compares to retatrutide — none of which is public.
📊 Correlative data
- Retatrutide is the closest read: same three receptors, same design logic, and considerably further along. The class-wide pattern so far is that the glucagon arm buys additional weight loss and additional gastrointestinal burden, and that titration is what makes it tolerable.
🧪 Theoretical / extrapolated
- The glucagon arm is what separates a triple from a dual. GLP-1 and GIP act mostly on intake and insulin handling; glucagon raises energy expenditure directly. That is the bet the whole triple-agonist class is making.
- Dose-precision-critical, like everything in this class — it goes in its own syringe, and it is titrated in volumes small enough that co-mixing compounds the error.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What UBT251 actually does
Three receptors, and the useful way to think about them is as three separate drugs sharing one syringe. UBT251 is described by its originator as a GLP-1 / GIP / glucagon triple receptor agonist. Each arm has its own biology, its own benefit and its own cost, and the compound's behavior is decided by the ratio between them.
The glucagon arm is the one that makes a triple different from a dual, and it is the one that cuts both ways. Glucagon-receptor agonism raises hepatic fat oxidation and whole-body energy expenditure — that is where weight loss beyond a GLP-1's comes from. It also raises hepatic glucose output, which is the opposite of what a diabetes drug wants, and it raises heart rate. A triple agonist works only if the incretin arms are strong enough to cover the glucose that the glucagon arm liberates. Get the ratio wrong and you have built a drug that burns fat and raises blood sugar.
What is published about UBT251's receptor pharmacology: nothing. No EC50 at any of the three receptors, no selectivity ratio, no cAMP assay, no binding constant, no sequence, no modification strategy. The compound has no peer-reviewed discovery paper. That is a normal position for an asset in early development and it is an abnormal position for something people are buying.
What the class's published chemistry looks like, for comparison. Coskun 2022 takes a triple agonist from discovery to clinical proof of concept in one paper — receptor pharmacology, preclinical models, first human data, all in Cell Metabolism. Urva 2022 is the phase 1b multiple-ascending-dose trial in people with type 2 diabetes, in the Lancet. Jastreboff 2023 is the phase 2 obesity trial in the New England Journal of Medicine. Three papers, three journals, one molecule, and any reader can check every number in them. That is the standard this compound has not yet met, and naming the standard is more useful than repeating that the compound is ‘early’.
And a structural point that follows from the dosing. Both announced UBT251 trials used weekly subcutaneous injection United Labs / Novo Nordisk 2025 · announcement United Labs 2026 · announcement. A peptide agonist does not last a week unless something has been done to it — typically fatty-acid acylation that binds it reversibly to albumin, the strategy behind every once-weekly incretin on the market. UBT251's structure has not been published, so which strategy was used, and therefore which drug interactions and which formulation constraints apply, cannot be stated. The weekly schedule is the only public evidence that any half-life extension exists at all.
Cell, rodent, human — and where it stops
This page has to make a distinction most pages do not: between what has been published and what has been announced. Published means a journal, a methods section, peer review, and numbers a stranger can interrogate. Announced means a company chose which figures to release. Both can be true. Only one is checkable, and for UBT251 everything is currently in the second category.
What has been announced, first trial. The licensing announcement of 24 March 2025 describes a completed phase 1b in China: randomized, double-blind, placebo-controlled, 36 patients across three dose groups, 12 weeks of weekly injections, in which “in the highest dose group, the average weight of the people who completed the trial decreased by 15.1% from baseline, while the average weight of people in the placebo group increased by 1.5%” United Labs / Novo Nordisk 2025 · announcement. Read the qualifier: the people who completed the trial. That is a completer analysis. It excludes anyone who stopped, and on an incretin-class drug the people who stop are disproportionately the people who could not tolerate the dose. No discontinuation figure was given.
What has been announced, second trial. On 24 February 2026 the originator and its licensee announced a randomized, double-blind, placebo-controlled phase 2 in 205 Chinese patients with obesity or overweight, dosed weekly subcutaneously at 2 mg, 4 mg and 6 mg or placebo for 24 weeks. The highest dose group was reported at 19.7% mean weight loss (−17.5 kg) against 2.0% (−1.6 kg) on placebo, with most common adverse events gastrointestinal, the vast majority mild to moderate and diminishing over time, and detailed data stated as due to be presented at a medical congress later that year United Labs 2026 · announcement. A separate announcement of 25 March 2026 reported a phase 2 in Chinese patients with type 2 diabetes with a mean HbA1c reduction of up to 2.16% at 24 weeks. Neither has been published; neither carries a citation chip on this page for that reason.
What has not been announced, and the list is longer than the list of what has. No adverse-event table with denominators. No discontinuation rate. No serious adverse events. No heart-rate data. No liver enzymes. No lipid or glucose data in the obesity trial. No protocol. No pre-registration reference. No receptor selectivity. No pharmacokinetics. The February release itself points at the gap: detailed data will be presented United Labs 2026 · announcement.
Why the licensing deal is evidence, and what kind. Novo Nordisk paid $200 million up front with up to $1.8 billion in milestones plus tiered royalties on sales outside China, Hong Kong, Macau and Taiwan, and the announcement records regulatory clearance to run trials in China for type 2 diabetes, obesity, MAFLD and chronic kidney disease and in the United States for type 2 diabetes, obesity and chronic kidney disease United Labs / Novo Nordisk 2025 · announcement. That is a serious, well-informed buyer who has seen the full dataset under diligence. It is meaningful evidence about the asset's commercial promise. It is not evidence about efficacy or safety in the sense a reader can use, because the diligence package is private and the buyer's opinion is not a result.
The obstacle, stated precisely. There is no peer-reviewed publication of any kind on UBT251 — no discovery paper, no preclinical study, no clinical trial report. Every number in circulation traces to two company announcements. The class it belongs to has phase 2 obesity data in the New England Journal of Medicine Jastreboff 2023, phase 1b diabetes data in the Lancet Urva 2022 and discovery-through-proof-of-concept in Cell Metabolism Coskun 2022. The gap between those two situations is the entire content of this page, and it is a gap in evidence availability rather than a claim that the compound does not work.
And one thing worth saying plainly for anyone buying a vial labeled with this name. A compound with no published sequence, no published structure and no reference standard in the public domain cannot be verified by any analysis a buyer can commission. With retatrutide a laboratory can at least compare against a published molecule. Here there is nothing to compare against.
UBT251 pharmacokinetics — how much of it actually gets in
There is no published pharmacokinetic data for UBT251 in any species, and this site's card says so honestly: ‘weekly dosing implies a long half-life; not publicly characterized’. That is the correct statement, and the useful thing to add is what the weekly schedule actually constrains.
The arithmetic of a weekly peptide. To dose once a week without the trough falling below the effective concentration, a peptide needs a half-life on the order of 100 to 170 hours — roughly four to seven days — which is what the once-weekly incretins achieve. A native incretin peptide's half-life is measured in minutes: it is cleaved by dipeptidyl peptidase-4 and filtered at the glomerulus. Getting from minutes to days requires two things: a DPP-4-resistant substitution near the N-terminus, and a mechanism to prevent renal filtration — in practice, a fatty-acid chain that binds albumin reversibly and turns a 4 kDa peptide into a 70 kDa complex the glomerulus cannot pass. UBT251 is dosed weekly United Labs / Novo Nordisk 2025 · announcement United Labs 2026 · announcement, so something of that kind has been done to it, and what has been done has not been disclosed.
Why that matters practically rather than academically. Albumin binding is the mechanism, and it is also the vulnerability: it makes exposure sensitive to albumin concentration, which falls in liver disease, nephrotic syndrome, inflammation and malnutrition. It also means that dose titration is slow — with a multi-day half-life, steady state takes four to five weeks, so the adverse effects of a dose escalation keep building for a month after the escalation. That is why every drug in this class is titrated over months, and it is why an announced 24-week trial United Labs 2026 · announcement spends much of its duration getting to the dose it is testing.
What clears it, by class inference. An acylated peptide agonist of this size is not a cytochrome-P450 substrate and has essentially no classical drug-drug interactions; it is broken down to amino acids by ubiquitous peptidases and by renal and hepatic proteolysis. The one real interaction any incretin has is pharmacodynamic and mechanical: delayed gastric emptying changes the absorption rate of everything swallowed alongside it. That applies here on class grounds, and it is stated as class reasoning rather than as a UBT251 finding, because no UBT251 finding exists.
There is no established dose outside a trial protocol. The announced phase 2 used 2, 4 and 6 mg weekly United Labs 2026 · announcement. Those are the only three numbers with any provenance at all, they were reached by titration inside a monitored protocol, and the 6 mg arm is the one carrying both the 19.7% weight-loss figure and the gastrointestinal adverse events.
What would have to be true, and how you would know it was not
Five predictions with a marker, a direction and a window. The third and fourth are the ones the glucagon arm forces, and they are the reason this molecule is not simply a stronger GLP-1.
1. Weight should fall on a months-long clock, not a weeks-long one. The announced phase 2 read out at 24 weeks, and the class titrates over months because of the multi-day half-life United Labs 2026 · announcement. Weigh fasted, same time of day, weekly, and judge nothing before 12 weeks. Anyone assessing a weekly-dosed incretin at four weeks is assessing the titration, not the drug.
2. Nausea and early satiety should appear first and settle. The announcement reports the most common adverse events as gastrointestinal, “the vast majority mild to moderate and diminished over time” United Labs 2026 · announcement. That pattern — onset with each dose increase, tachyphylaxis over the following weeks — is the GLP-1 arm working. Its complete absence at a dose that is producing weight loss would be unusual and worth investigating.
3. Resting heart rate should rise, and the glucagon arm makes that larger here than for a plain GLP-1. Robinson 2013 meta-analyzed 32 trials of GLP-1 agonists and found heart rate up 1.86 bpm (95% CI 0.85 to 2.87) versus placebo, with the effect more evident for long-acting preparations. Glucagon-receptor agonism raises heart rate independently on top of that. Log resting heart rate on waking, daily, from before the first dose. This is the cheapest safety monitoring available for this class and no announced UBT251 dataset has reported it.
4. The prediction that cuts against it: fasting glucose could go the wrong way, and liver enzymes deserve watching. The glucagon-receptor arm raises hepatic glucose output. In a person without diabetes, whose incretin arms have less glucose-lowering work to do, that push is less opposed. Draw Fasting Glucose and Hemoglobin A1c (HbA1c) at baseline and 12 weeks, and draw ALT and AST alongside them, since the same arm is reprogramming hepatic substrate handling and the announced development program includes a MAFLD indication United Labs / Novo Nordisk 2025 · announcement. This is class-level reasoning, labeled as such: the announced diabetes trial reported HbA1c falling by up to 2.16%, in patients whose incretin arms had a great deal of work to do.
5. Lean mass should be measured, because nobody has reported it. Rapid weight loss of the magnitude announced — 17.5 kg in 24 weeks United Labs 2026 · announcement — carries a lean-mass cost that no announcement for this compound has quantified. DEXA at baseline and at 24 weeks, with resistance training and protein intake recorded, is the measurement that turns a scale number into a body-composition result. It is the single most valuable thing an individual user of this class can contribute.
What nobody has tested yet
Nobody outside two companies has seen a UBT251 dataset. The obvious and entirely conventional experiment is to publish: the phase 1b and the two phase 2 trials, with methods, an intention-to-treat analysis, an adverse-event table and discontinuation rates. The February 2026 announcement says detailed data will be presented at a medical congress United Labs 2026 · announcement. Until that happens, the difference between this molecule and a published one is not a difference in quality — it is that one can be checked.
Nobody has published the receptor potency ratio. For a multi-agonist the ratio across GLP-1, GIP and glucagon receptors decides how much heart rate is bought per kilogram, whether fasting glucose rises or falls, and whether fat comes off liver or off limb. It has not been disclosed for UBT251. Worth noting for balance: it is frequently absent for published molecules too, so this is a field-level gap that UBT251 inherits rather than a unique omission.
Nobody has run this compound against a published triple. The comparison anyone would want — UBT251 against retatrutide, same protocol, same population, weight and HbA1c and heart rate and lean mass — does not exist, and the two programs' announced results come from different countries, different populations and different trial designs. The announced 19.7% at 24 weeks United Labs 2026 · announcement and the published 24.2% at 48 weeks for retatrutide Jastreboff 2023 are not comparable numbers, and any page setting them side by side without saying so is misleading its reader.
UBT251 — its own safety story, not its class's
The honest headline is that there is no safety dataset for this compound in the public domain. Not a thin one — none. No adverse-event table with denominators, no serious-adverse-event count, no discontinuation rate, no laboratory safety data, no electrocardiogram data. The only safety statement anyone outside the two companies has is one sentence: most common adverse events gastrointestinal, “the vast majority mild to moderate and diminished over time” United Labs 2026 · announcement. That sentence was written by a party with an interest in it, which does not make it false and does make it unverifiable.
What the class's risks are, applied here as class reasoning and labeled as such. Every incretin multi-agonist carries: gastrointestinal effects that are dose-limiting during titration; delayed gastric emptying, which is a genuine hazard around anesthesia and sedation because it raises aspiration risk; gallbladder disease driven by rapid weight loss; pancreatitis as a labeled concern across the class; and a small, reproducible rise in heart rate Robinson 2013. None of these has been quantified for UBT251.
The glucagon arm adds two more that a dual agonist does not. Hepatic glucose output rises, so the glycemic effect in a non-diabetic person is less predictable than in the diabetic population the announced HbA1c figure came from; and the same arm changes hepatic substrate handling, which is why the development program includes MAFLD as a target indication United Labs / Novo Nordisk 2025 · announcement. An effect large enough to be worth treating a liver disease with is an effect large enough to be worth measuring in a healthy liver.
The completer-analysis caveat is a safety point, not a statistical one. The 15.1% weight-loss figure from the phase 1b was reported for “the people who completed the trial” United Labs / Novo Nordisk 2025 · announcement. On drugs of this class, the people who do not complete are largely the people who could not tolerate them — so a completer analysis reports the efficacy of the drug in exactly the population that did not experience its worst effects, and reports nothing about how large that excluded group was. That is the single most important thing to understand about the numbers on this page.
And the risk that is specific to buying this rather than to taking it. UBT251 is a clinical-stage asset, licensed for $200 million up front United Labs / Novo Nordisk 2025 · announcement, with no approved product anywhere and no published structure or sequence. Anything sold under this name outside a trial has no reference standard to be checked against, no certificate of analysis that can mean anything specific, and no way for a laboratory to confirm identity. With a published molecule, mass spectrometry can at least be compared to a literature value. Here there is no literature value. That is a different and harder problem than ordinary purity risk.
Sources read for this page
- Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.. N Engl J Med 2023 · PMID 37366315
- Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.. Cell Metab 2022 · PMID 35985340
- Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.. Lancet 2022 · PMID 36354040
- Robinson LE, Holt TA, Rees K. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.. BMJ Open 2013 · PMID 23355666
- The United Laboratories International Holdings and Novo Nordisk. Exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist, with phase 1b results quoted in the announcement (not peer-reviewed).. Company announcement, 24 March 2025
- The United Laboratories International Holdings and Novo Nordisk. Announcement of Chinese phase 2 obesity results for UBT251 - 205 patients, 24 weeks (media release; detailed data stated as due at a medical congress, not peer-reviewed).. Company announcement, 24 February 2026
UBT251 — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These slow gastric emptying and act on hypothalamic and brainstem appetite centers. Almost everything that goes wrong follows from the gastric emptying, not from anything exotic: nausea, early fullness, reflux, constipation, and — when someone titrates faster than their gut adapts — vomiting.
- The composition risk is the one nobody warns about. Appetite suppression does not discriminate. It suppresses the appetite for protein too, and in a deficit without adequate protein and a resistance stimulus a meaningful share of the loss is lean mass. That lowers the maintenance intake you eventually eat back into, which is the mechanism behind most of the rebound stories.
- Slowed emptying also delays absorption of anything else taken by mouth — a pharmacokinetic consequence rather than a drug interaction, but it matters for anything time-critical.
What has actually been reported
- GI effects are extremely common and mostly settle over weeks. Gallbladder problems are a recognized signal, and rapid weight loss of any cause raises gallstone risk — the drug is not doing something unusual, it is doing rapid weight loss well.
- Pancreatitis is reported and rare. The presentation to know is severe upper abdominal pain radiating to the back, usually with vomiting.
- A thyroid C-cell tumor signal exists in rodents and has not been demonstrated in humans; it is why the labeled contraindication for medullary thyroid carcinoma and MEN2 exists.
How to reduce the risk
Same mechanism as the prediction.
- Follow the titration schedule even if you feel fine. It exists for gut adaptation, not for legal cover. Almost everyone who quits in the first month escalated faster than their stomach could keep up.
- Hit your protein target first at every meal, before anything else on the plate. This is the single highest-leverage habit on the drug — 1.6–2.2 g/kg, and eat it while you still have the appetite to.
- Lift while you are on it. The compound handles intake; resistance training is the only thing handling what you keep.
- Aim for 0.5–1% of bodyweight per week, deliberately. The drug removes the hunger signal that would normally stop you going too hard, so the rate has to be a decision rather than a by-product.
- Fiber and electrolytes from day one, not from week four when constipation has already made up your mind about the drug.
- If nausea is winning, step back one dose rather than quitting the class. Almost nobody needs to be at the top of the range.
What it does to your bloodwork
A fact about the assay.
- HbA1c and fasting glucose should improve — that is the drug working, and it is the cleanest confirmation you have.
- Rapid loss moves lipids, liver enzymes and uric acid transiently. A wobble at 8 weeks into aggressive loss is usually the loss, not a new problem — but it is a reason to have the baseline.
- Worth a thyroid panel and a lipid panel before starting, simply so a later result has something to be compared against.
Don't run this if
- Personal or family history of medullary thyroid carcinoma, or MEN2.
- Previous pancreatitis.
- Active gastroparesis — you would be adding a drug whose main action is the thing already wrong.
The honest unknown
- What happens to body composition over repeated multi-year cycles of loss and regain on and off these drugs. Weight is well studied; the muscle-to-fat ratio of what comes back is not.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
UBT251 — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What UBT251 moves on your bloodwork
Expected direction, not a measured one.
- HbA1c (Hemoglobin A1c) — ↓ expected to fall
Falling HbA1c is the compound working. Expect it.
What to do: Baseline and 12 weeks. It moves slowly by design — a 4-week retest tells you very little. - Fasting Insulin — ↓ expected to fall
Insulin sensitivity improves as weight falls and the incretin effect restores first-phase insulin release.
What to do: Useful alongside HbA1c; the two together read the trend properly. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to fall
Triglycerides in particular fall with weight loss and improved insulin sensitivity.
What to do: Re-check at 12 weeks rather than chasing early numbers. - Lipase — ↑ expected to rise
Lipase and amylase can rise without pancreatitis on this class. An isolated mild elevation in someone with no symptoms is common.
What to do: Severe, persistent abdominal pain radiating to the back is the thing that matters, not the number. Symptoms decide, not a mild enzyme rise. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Rapid weight loss and reduced intake shift electrolytes and kidney markers; dehydration from nausea or vomiting shows up here first.
What to do: Worth a baseline. If you have been vomiting, this is the panel that catches the consequence. - Ferritin — ↓ expected to fall
Not the drug — the eating. Sharply reduced intake drops iron, B12 and protein intake with it, and this is the most commonly missed consequence of a good response.
What to do: Check ferritin and B12 at 12 weeks. Muscle loss and hair shedding on a GLP-1 is very often a nutrition problem wearing a drug's name.
The pattern with this class is that the frightening-looking numbers (lipase) are usually fine and the boring ones (ferritin, B12) are where the real damage happens.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — UBT251 in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside UBT251
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Where you started, so you can prove the change was real |
| Fasting Insulin | Moves years before HbA1c does — the earliest signal you get |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Rapid fat loss shifts triglycerides fast, in both directions |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes while intake is restricted |
The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.
Check results you already have → · All 103 markers A–Z
UBT251 — frequently asked questions
What is UBT251?
UBT251 (Vistrutide — GLP-1 / GIP / glucagon triple agonist) is a metabolic & fat loss research compound. A triple agonist at the GLP-1, GIP and glucagon receptors — the same three-receptor design as retatrutide. The glucagon arm is what separates the triples from the duals: glucagon raises energy expenditure directly rather than only suppressing intake, which is the mechanism the class is betting on for larger weight loss.
Where can I find UBT251 dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full UBT251 protocol are available to members inside Skool. This public page covers what UBT251 is, how it works and the evidence.
What is the half-life of UBT251?
UBT251 has an approximate half-life of Weekly dosing implies a long half-life; not publicly characterized, which is part of what determines how often it's dosed.
What's the evidence behind UBT251?
Current evidence level: Human (early clinical, United Biotechnology; rights licensed to Novo Nordisk in 2026). UBT251 is offered for research purposes only and is not an approved medicine.
What UBT251 is used for
UBT251 appears under 2 goals in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.